miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14

Zheng, Liduan; Jiao, Wanju; Hong, Ming; Song, Huajie; Li, Dan; Xuan, Xuenan; Chen, Yajun; Yang, Feng; Li, Huanhuan; Huang, Kai; Tong, Qiangsong

doi:10.18632/oncotarget.9739

Cited by 51 publications

(71 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,26 In gastric cancer, miR-337 could inhibit the metastasis of cells through targeting MMP14. [25][26][27] When the patients has the lower expression of miR-337, they may easier to be found have lymph node metastasis in gastric cancer. MiR-337 could promote the expression of casein kinase II subunit a and then regulate the growth of colorectal cancer cells.…”

Section: Discussionmentioning

confidence: 99%

miR-337 can be a key negative regulator in melanoma

Xiao

Yao

Zheng

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Incidence of melanoma is increasing annually worldwide. There remains a lack of suitable treatment methods which can significantly improve the 5-year survival rates of patients. It is established that micro RNAs (miRNAs) have important roles in the diagnosis and treatment of cancer. MiR-337 had been reported to regulate the development of variety of cancers, as a cancer suppressive factor. In our research we found that miR-337 had a lower expression in melanoma than adjacent tissues. The patients who had a lower miR-337 also got a worse survival. MiR-337 could target STAT3 to regulate the occurrence and development of melanoma. In summary, our findings suggest that the miR-337/STAT3 axis may serve as a potential target for the treatment of melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

miR-337 can be a key negative regulator in melanoma

Xiao

Yao

Zheng

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] It is difficult to diagnosis this deadly disease at an early stage as there are no specific symptoms. [1][2][3][4][5] It is difficult to diagnosis this deadly disease at an early stage as there are no specific symptoms.…”

Section: Introductionmentioning

confidence: 99%

LincRNA‐p21 enhances the sensitivity of radiotherapy for gastric cancer by targeting the β‐catenin signaling pathway

Chen

Yuan

Yang

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are a large and diverse class of transcribed RNA molecules with a length of more than 200 nucleotides that modulate the gene expression at the posttranscriptional or transcriptional level. LncRNAs played crucial roles in many biological processes, such as cell proliferation, metastasis, and migraton. In this study, we evaluated the role of lincRNA‐p21 in the gastric cancer (GC). We demonstrated that the expression level of lincRNA‐p21 was downregulated in the GC tissues and cell lines. Moreover, ectopic expression of lincRNA‐p21 suppressed the GC cell growth, cell cycle, and migration. Furthermore, we demonstrated that the X‐ray increased the expression level of lincRNA‐p21 in both the HCG‐27 and SGC7901 cells and elevated expression of lincRNA‐p21 increased the radiotherapy sensitivity of the GC cell. In addition, we showed that ectopic expression of lincRNA‐p21 suppressed the β‐catenin and c‐myc expression. Overexpression of lincRNA‐p21 inhibited the GC cell proliferation and increased the radiosensitivity of GC cells by regulating the β‐catenin signaling pathway. These data suggested that lincRNA‐p21 acted as a tumor suppressor gene in the development of GC.

show abstract

“…75 articles were further removed because of non-DSC or the samples were not detected in protein expression levels or were not derived from tissue. Finally, 20 eligible articles [42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61] were included in this meta-analysis (Table 1).…”

Section: Identification Of the Eligible Studiesmentioning

confidence: 99%

Expression of MMP-14 and prognosis in digestive system carcinoma: a meta-analysis and databases validation

Duan¹,

Peng²,

Yin³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background:The Matrix metalloproteinase-14 (MMP-14) expression has been shown to be overexpressed in different cancers. However, there is no comprehensive quantitative evaluation of the MMP-14 prognostic value in digestive system carcinoma (DSC). The aim of this study is to explore the correlation between the MMP-14 expression and DSC prognosis. Methods: We conducted a meta-analysis to estimate the association strength between MMP-14 expression and prognosis. GEPIA and Kaplan Meier plotters were used to assess overall survival (OS), disease-free survival (DFS)/progression-free survival (PFS) in DSC patients and the differential expression of MMP-14 in DSC tissues and adjacent tissues. Results: A total of 20 studies including 2,519 patients with OS and 438 patients with DFS/PFS data were analyzed in evidence synthesis. Overall, the combined hazard ratio (HR) with 95% confidence interval (95% CI) was 1.98 (95%Cl: 1.77-2.22, P<0.001) for OS and 3.61 (95%Cl: 2.39-5.43, P<0.001) for DFS/PFS. For subgroup analyses, significant correlations were revealed between increased MMP-14 expression and poor OS in patients with gastric cancer (HR=2.21, 95%CI: 1.76-2.77, P<0.001), esophageal carcinoma (HR=2.01, 95%CI: 1.58-2.57, P<0.001), oral cancer (HR = 1.69, 95% CI: 1.30-2.20, P < 0.001) (HR=2.14, 95%CI 1.35-2.19, P<0.001) and hepatocarcinoma. In database verification analyses, the MMP-14 expression levels in normal tissues were significantly higher than that in DSC tissues, and significant associations were observed between high MMP-14 expression levels and poor prognosis. Conclusions:The high expression levels of MMP-14 might predict poor prognosis in DSC. Larger prospective clinical cohort studies are required to validate the prognostic role.

show abstract

miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14

Cited by 51 publications

References 52 publications

miR-337 can be a key negative regulator in melanoma

miR-337 can be a key negative regulator in melanoma

LincRNA‐p21 enhances the sensitivity of radiotherapy for gastric cancer by targeting the β‐catenin signaling pathway

Expression of MMP-14 and prognosis in digestive system carcinoma: a meta-analysis and databases validation

Contact Info

Product

Resources

About